ArticleNeuro-oncology2013
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.
Article in Neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review.Palliative medicine · 2017Pooled it
- Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Arsenic Trioxide and the MNK1 Inhibitor AUM001 Exert Synergistic Anti-Glioblastoma Effects by Modulating Key Translational, Cell Cycle, and Transmembrane Transport Pathways.Brain sciences · 2026Article
- The role of DNA methylation in directing treatment in medulloblastoma.Epigenomics · 2025Review
- Targeting the Mitochondria in High-Grade Gliomas.Cancers · 2025Review
- Arsenic enhances cervical cancer cell radiosensitivity by suppressing the DNA damage repair pathway.Translational cancer research · 2025Article
- Pharmacological Phase I Clinical Trials in Pediatric Brain Tumors (1990-2024): A Historical Perspective.Oncology research · 2025Review
- Review
- Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma.Frontiers in neurology · 2022Article
- The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?Cellular and molecular life sciences : CMLS · 2021Review
- Autophagy as a Potential Therapy for Malignant Glioma.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation ofOncotarget · 2018Article
- Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.Oncotarget · 2017Article
- Drug repurposing for glioblastoma based on molecular subtypes.Journal of biomedical informatics · 2016Article
- Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors.Neuro-oncology · 2015Article
- Mechanisms regulating glioma invasion.Cancer letters · 2015Review
- Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.Journal of molecular neuroscience : MN · 2015Article
- Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma.Frontiers in oncology · 2015Review
- The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas.European journal of medical research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundArsenic trioxide (ATO) has demonstrated preclinical evidence of activity in the treatment of infiltrating astrocytomas.
methodsWe conducted a phase I trial of ATO given concomitantly with radiation therapy in children with newly diagnosed anaplastic astrocytoma, glioblastoma, or diffuse intrinsic pontine glioma. Eligible patients received a fixed daily dose of 0.15 mg/kg of ATO once a week, with each subsequent cohort of patients receiving an additional dose per week up to a planned frequency of ATO administration 5 days per week as tolerated. Twenty-four children were enrolled and 21 children were evaluable.
resultsATO was well tolerated throughout the entire dose escalation, resulting in confirmation of safety when administered 5 days per week during irradiation.
conclusionsThe recommended dose of ATO during conventional irradiation is 0.15 mg/kg given on a daily basis with each fraction of radiation therapy administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.